Tiemin Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tiemin Sun has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Caijuan Hu
College of Life and Health Sciences, Northeastern University, Shenyang 110819, China
1 shared publicationHao Su
College of Life and Health Sciences, Northeastern University, Shenyang 110819, China
1 shared publication- Hong Yang
Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
1 shared publication J. Paul Fawcett
School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, New Zealand
1 shared publicationJiang Yu
Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang, 110016, China; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China
1 shared publicationJinghan Luo
Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Shenyang 110016, China
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 227, 113898
Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 227, 113898
Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2
- 1 December 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (23-24) , 6035-6049
Design, synthesis and antifungal evaluation of borrelidin derivatives
- 1 December 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (23-24) , 6035-6049
Design, synthesis and antifungal evaluation of borrelidin derivatives
- Open Access
Phenolic Esters of O-Desmethylvenlafaxine with Improved Oral Bioavailability and Brain Uptake
O-Desmethylvenlafaxine (desvenlafaxine, ODV) is a recently approved antidepressant which in some clinical studies failed to meet a satisfactory end-point. The aim of this study was to prepare a series of phenolic esters of ODV and evaluate their potential as ODV prodrugs with improved brain uptake. Fifteen phenolic esters (compounds 1a–o) were synthesized and their pharmacokinetic profiles evaluated in rat. The four compounds producing the highest relative bioavailability of ODV in rat (compounds 1c, 1 e, 1n, 1o) were then studied to evaluate their brain uptake. Of these four compounds, compound 1n (the piperonylic acid ester of ODV) demonstrated the highest Cmax of ODV both in the rat hypothalamus and total brain. Finally the pharmacokinetics of 1n were evaluated in beagle dog where the increase in relative bioavailability of ODV was found to be as great as in rat. This high relative bioavailability of ODV coupled with its good brain penetration make 1n the most promising candidate for development as an ODV prodrug.
Open AccessPhenolic Esters of O-Desmethylvenlafaxine with Improved Oral Bioavailability and Brain Uptake
O-Desmethylvenlafaxine (desvenlafaxine, ODV) is a recently approved antidepressant which in some clinical studies failed to meet a satisfactory end-point. The aim of this study was to prepare a series of phenolic esters of ODV and evaluate their potential as ODV prodrugs with improved brain uptake. Fifteen phenolic esters (compounds 1a–o) were synthesized and their pharmacokinetic profiles evaluated in rat. The four compounds producing the highest relative bioavailability of ODV in rat (compounds 1c, 1 e, 1n, 1o) were then studied to evaluate their brain uptake. Of these four compounds, compound 1n (the piperonylic acid ester of ODV) demonstrated the highest Cmax of ODV both in the rat hypothalamus and total brain. Finally the pharmacokinetics of 1n were evaluated in beagle dog where the increase in relative bioavailability of ODV was found to be as great as in rat. This high relative bioavailability of ODV coupled with its good brain penetration make 1n the most promising candidate for development as an ODV prodrug.